First-line treatment study for advanced small cell esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old.
- Your cancer is confirmed as small cell cancer of the esophagus, and it can’t be removed by surgery or has spread/returned.
- You have not had any “systemic” anti-cancer treatment before (treatments that travel through the body).
- If you previously had chemo with surgery or chemo with radiation for a curative attempt, the cancer must have come back or spread more than 6 months after that treatment ended.
- You must have at least one measurable tumor spot and be fit for treatment based on standard blood test and heart/lung status (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation for esophageal small cell carcinoma. The goal is to see if this combination improves outcomes for patients who have not been treated before.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
This study tests whether choosing a treatment based on specific biomarkers (biological clues) works better than the standard approach for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) that has not been treated yet. It aims to improve outcomes by tailoring therapy to each person's cancer.
This trial tests a combination of a new drug (SYS6010), an immunotherapy called enlonstobart, and standard chemotherapy as the first treatment for esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Hear when a new Esophageal Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.